Why Clovis Oncology Fell 7.1% in August
Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed to the company sharing good and bad news with investors during in its second-quarter report.
Here's a review of the headline numbers from the company's second quarter:
Financial updates aside, Clovis also had several other highlights to share with investors:
Source: Fool.com
Bristol-Myers Squibb Stock
€49.16
0.470%
Currently there is a rather positive sentiment for Bristol-Myers Squibb with 6 Buy predictions and 3 Sell predictions.
As a result the target price of 58 € shows a slightly positive potential of 17.98% compared to the current price of 49.16 € for Bristol-Myers Squibb.